Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

Henry20feb_ Dec. 4 at 9:24 AM

$AYTU - Pipeline Fabre-Kramer Pharmaceuticals (among others): Platform: Antidepressants (EXXUA™, NDA); Mayor Depression (FKB01MB Fase-2); Anxiolytics (EXXUA™, Fase-3) etc.

0 · Reply

Chachix Dec. 3 at 7:33 PM

$AYTU. Another Event incoming!!! More Lies And Theft From Dishbrow, Poshit wants money From Christmas!!! Let’s Give Him The Handcuffs and A 22 Inch When In Orange Suite!!! S C A M. A L E R T!!!

0 · Reply

Henry20feb_ Dec. 3 at 9:03 AM

$AYTU Adoption simulation of EXXUA (moderate success) Year 1, Launch: New MDD prescriptions annually: ~70 million / EXXUA captures 0.3–0.8% of new starts / Patients on EXXUA: 50k–120k / Revenue: ~$90M – $250M (typical for a new antidepressant with a new mechanism but modest early marketing).

0 · Reply

Henry20feb_ Dec. 3 at 8:16 AM

$AYTU EXXUA (gepirone) was invented/synthesized by Bristol-Myers Squibb (with Mead Johnson), but the formulation and final product EXXUA was developed and marketed by Fabre-Kramer Pharmaceuticals (current owner). Aytu’s role is to market it in the U.S.

0 · Reply

inv1ncible Nov. 27 at 5:33 PM

$AYTU offering then reverse split a year from now

0 · Reply

Love_To_Learn Nov. 26 at 8:30 PM

SECURING LIQUIDITY OFF 1.58/1.63 TO UNLEASH WHILE SIDE NOTE 1.80 KEY $ZYXI CHANGING IT WITH ORIGINAL 1.8 KEY HOLDER WHICH IS $AYTU NOT $PSTV

1 · Reply

Henry20feb_ Nov. 25 at 12:40 PM

$AYTU Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference 2/3 December 2025

0 · Reply

Henry20feb_ Nov. 24 at 10:18 AM

$AYTU xConnect adds strategic value and turns Aytu into a platform company, not just a single-drug story. Increases attractiveness for BD deals and M&A. Future in-licensed CNS assets immediately benefit from the same infrastructure.

1 · Reply

Henry20feb_ Nov. 24 at 9:36 AM

$AYTU RxConnect gives: Distribution control – unique infrastructure vs. outsourced peers / Economic leverage – meaningfully higher and more stable margins / Physician/patient stickiness – once integrated, switching costs grow / Launch acceleration – especially critical for EXXUA in MDD. If EXXUA launches successfully and Aytu drives high RxConnect routing (50–75%+), the platform will meaningfully differentiate commercial performance vs. peers — and could become the company’s most valuable intangible asset.

1 · Reply

Henry20feb_ Nov. 22 at 11:27 AM

$AYTU NasdaqCM: AYTU Insider Trading Volume November 21st 2025

0 · Reply

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 13, 2025, 9:21 PM EST - 21 days ago

Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 21 days ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 4 weeks ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Oct 28, 2025, 9:00 AM EDT - 5 weeks ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 10, 2025, 9:00 AM EDT - 7 weeks ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Sep 24, 2025, 4:15 PM EDT - 2 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 23, 2025, 9:43 PM EDT - 2 months ago

Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript

Sep 23, 2025, 4:05 PM EDT - 2 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 2 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 9, 2025, 4:30 PM EDT - 6 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Jun 6, 2025, 8:01 AM EDT - 6 months ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 6 months ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

May 14, 2025, 8:29 PM EDT - 7 months ago

Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 7 months ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 7 months ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 21, 2025, 4:05 PM EDT - 8 months ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Feb 12, 2025, 6:27 PM EST - 10 months ago

Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript

Feb 12, 2025, 4:03 PM EST - 10 months ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 5, 2025, 5:50 PM EST - 10 months ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 11 months ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 7:25 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 6:51 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 8:28 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 8, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 10:52 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

Feb 14, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024, 4:15 PM EST - 1 year ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Jan 23, 2024, 9:00 AM EST - 2 years ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 7:30 PM EST - 2 years ago

Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Henry20feb_ Dec. 4 at 9:24 AM

$AYTU - Pipeline Fabre-Kramer Pharmaceuticals (among others): Platform: Antidepressants (EXXUA™, NDA); Mayor Depression (FKB01MB Fase-2); Anxiolytics (EXXUA™, Fase-3) etc.

0 · Reply

Chachix Dec. 3 at 7:33 PM

$AYTU. Another Event incoming!!! More Lies And Theft From Dishbrow, Poshit wants money From Christmas!!! Let’s Give Him The Handcuffs and A 22 Inch When In Orange Suite!!! S C A M. A L E R T!!!

0 · Reply

Henry20feb_ Dec. 3 at 9:03 AM

0 · Reply

Henry20feb_ Dec. 3 at 8:16 AM

0 · Reply

inv1ncible Nov. 27 at 5:33 PM

$AYTU offering then reverse split a year from now

0 · Reply

Love_To_Learn Nov. 26 at 8:30 PM

SECURING LIQUIDITY OFF 1.58/1.63 TO UNLEASH WHILE SIDE NOTE 1.80 KEY $ZYXI CHANGING IT WITH ORIGINAL 1.8 KEY HOLDER WHICH IS $AYTU NOT $PSTV

1 · Reply

Henry20feb_ Nov. 25 at 12:40 PM

$AYTU Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference 2/3 December 2025

0 · Reply

Henry20feb_ Nov. 24 at 10:18 AM

1 · Reply

Henry20feb_ Nov. 24 at 9:36 AM

1 · Reply

Henry20feb_ Nov. 22 at 11:27 AM

$AYTU NasdaqCM: AYTU Insider Trading Volume November 21st 2025

0 · Reply

Henry20feb_ Nov. 22 at 11:20 AM

$AYTU EXXUA (gepirone ER) First-in-class 5-HT1A receptor agonist for MDD / Entering a $22B U.S. depression market / A new chemical entity (NCE) with a recently extended patent to 2030 / Manufacturing and logistics on track for December 2025 shipments / Sales force almost fully trained / Promotional and patient support materials nearly complete / Pricing established / Payer negotiations underway / Integration into RxConnect® nearly complete / KOL engagement and conferences already in progress (Aytu’s press release).

0 · Reply

DubsFan Nov. 21 at 5:20 PM

$AYTU outstanding job Joshy, my family is splitting a cornish game hen Thursday thanks to your leadership

0 · Reply

Henry20feb_ Nov. 20 at 11:13 AM

$AYTU RxConnect is AYTU’s proprietary patient-access and support platform (ca. 1,000 pharmacies connected). So it’s not just product manufacturing/sales, but also patient uptake, refills, distribution / gives data insights that many pharma firms don’t fully own (especially small/medium ones) / It can drive higher adherence, which is critical for specialty drugs and longer-term therapies / It acts as a launch platform for EXXUA, which is differentiated and potentially high value; having an existing access infrastructure lowers launch risk!

0 · Reply

Henry20feb_ Nov. 19 at 11:02 AM

$AYTU ADHD revenue ($13.2M vs $15.3M YoY) is the company's current cash engine, and 85% of prescriptions go through their proprietary RxConnect model, giving them pricing stability and strong patient adherence. A 10% normalized growth rate is impressive for a mature ADHD portfolio.

1 · Reply

Love_To_Learn Nov. 17 at 12:40 PM

$TRUG giving 1.80 key access to original 1.80 holder that is $AYTU actually not $PSTV the true holder of this was aytu but swapped for beloved with pat that we undid ! now to incorporate pre RS $FLYY pre RS after my manipulation on them and i will require a host for this let us use GTI now $GTIJF

1 · Reply

Deathmetaldarrel Nov. 17 at 4:41 AM

$AYTU Bobby Liebling…Pentagram

0 · Reply

Alain_Simard Nov. 15 at 12:05 AM

$AYTU calm down folks!!! You will all get a chance to average down at $0.50 shortly… you didn’t miss your opportunity!! 😂😂😂

0 · Reply

Telorino Nov. 14 at 10:13 PM

$AYTU never fails to disappoint! By the end of the day it dropped all the days gains…

0 · Reply

Henry20feb_ Nov. 14 at 9:35 AM

$AYTU Cash: $32.6M provides: Multi-quarter runway for the EXXUA launch / Buffer for sales force expansion and inventory buildup / Reduced need for near-term dilution or debt.

0 · Reply

Market Cap	20.89M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	1.17

Volume	51,600
Avg Vol	161,840
Day's Range	N/A - N/A
Shares Out	10.19M
Stochastic %K	76%
Beta	0.28
Analysts	Strong Sell
Price Target	$9.17